A Woman with Rheumatoid Arthritis Who Successfully Delivered a Healthy Child with Continuous Administration of Sarilumab Throughout Pregnancy

Satoshi Mizutani; Yuki Okunishi; Tatsuya Tamada; Hiroyuki Tanaka; Yuhei Ito; Yoshiki Yamamoto; Asa Kitamura; Hiroaki Tanaka; Tomoaki Ikeda; Ayako Nakajima

doi:10.2169/internalmedicine.9607-22

CASE REPORTS

A Woman with Rheumatoid Arthritis Who Successfully Delivered a Healthy Child with Continuous Administration of Sarilumab Throughout Pregnancy

Satoshi Mizutani, Yuki Okunishi, Tatsuya Tamada, Hiroyuki Tanaka, Yuhei Ito, Yoshiki Yamamoto, Asa Kitamura, Hiroaki Tanaka, Tomoaki Ikeda, Ayako Nakajima

Author information

Satoshi Mizutani
Center for Rheumatic Diseases, Mie University Hospital, Japan
Yuki Okunishi
Center for Rheumatic Diseases, Mie University Hospital, Japan
Tatsuya Tamada
Center for Rheumatic Diseases, Mie University Hospital, Japan
Hiroyuki Tanaka
Center for Rheumatic Diseases, Mie University Hospital, Japan
Yuhei Ito
Center for Rheumatic Diseases, Mie University Hospital, Japan
Yoshiki Yamamoto
Center for Rheumatic Diseases, Mie University Hospital, Japan
Asa Kitamura
Department of Obstetrics and Gynecology, Mie University Faculty of Medicine, Japan
Hiroaki Tanaka
Department of Obstetrics and Gynecology, Mie University Faculty of Medicine, Japan
Tomoaki Ikeda
Department of Obstetrics and Gynecology, Mie University Faculty of Medicine, Japan
Ayako Nakajima
Center for Rheumatic Diseases, Mie University Hospital, Japan

Keywords: rheumatoid arthritis, pregnancy, sarilumab, interleukin-6 inhibitor, assisted reproductive technology, infertility

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 4 Pages 633-636

DOI https://doi.org/10.2169/internalmedicine.9607-22

Browse “Advance online publication” version

Details

Abstract

We herein report a patient with rheumatoid arthritis (RA) who successfully delivered a healthy child with continuous administration of sarilumab throughout pregnancy. She delivered her first child, a healthy boy, following in vitro fertilization-embryo transfer (IVF-ET) while using etanercept and low-dose prednisolone. Disease activity persisted after delivery, so etanercept was switched to sarilumab. She became pregnant by IVF-ET again. Because RA was still active, sarilumab was continued during pregnancy. She delivered a healthy girl at the 38th week of gestation by Caesarean section. No abnormalities were detected at or within 6 months after birth. Sarilumab was safe and effective in this pregnant woman with RA.

Corresponding author

Register with J-STAGE for free!